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Tailoring research to stakeholdersAs we have emphasized before, the patients’ perspective
is key in clinical research [1]. This insight is far from new,
and consistent with Hippocrates’ principles of patient-
centeredness and seeking for evidence as a basis for good
patient care [2]. Accordingly, nowadays efforts to integrate
evidence-based health care, personalized medicine, and
patient-centered approaches are logical steps in a longstand-
ing tradition. In modern terms, we say that patients and
consumers are the most central stakeholders in clinical re-
search. However, finding ways to engage their perspectives
in research still leaves much room for improvement, as is
highlighted in this issue. But at the same time, there are
other societal parties that have great interest in the agenda
and contents of clinical research, such as professionals, pol-
icy makers, insurers, research organizations, journalists,
and industry.
While science- and investigator-driven research is deci-
sive for long-term health care innovation, engagement of
stakeholders helps practice-driven research to address is-
sues that are considered of major importance for care,
health, and quality of life. However, despite the attention
paid to research priority setting in recent years [3], the
methodology of engaging stakeholders in research is still
in an early phase and not systematically described. We
therefore welcome the contribution of Guise et al., who re-
viewed current practices for engaging stakeholders in prior-
itizing research, based on literature and interviews with
representatives of leading research organizations and of
evidence-based practice centers that engage stakeholders
in research. The authors conclude that consistent and ex-
plicit terminology about stakeholders and engagement
methods is essential, and that in-person techniques and
quantitative methods are important for generating ideas
and research prioritization. They also developed a checklist
for reporting stakeholder involvement.
Patients who receive a treatment they prefer may be
more motivated to adhere to treatment, which may result
in a better outcome. Franco and colleagues systematically
reviewed how patient preferences have been measured
and analyzed in clinical trials evaluating treatments for
musculoskeletal conditions. The methodological limitations
they found in the available evidence suggest that it is too
early to conclude whether patients’ preferences indeed af-
fect the trial outcome. For future trials they recommend
subgroup analysis based on appropriately measured patient
preferences. This connects to the work of Schmidt et al.,0895-4356/$ - see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jclinepi.2013.03.004who considered that while RCTs typically yield an
estimate for the intervention effect for the ‘average patient,’
clinical practice is targeted on individually tailored care.
Accordingly, rather than the main effect estimates, sub-
group analyses would move toward more personalized care.
Therefore, in a systematic review they compared subgroup-
specific and interaction effects between observational
studies, RCTs, and individual patient data meta-analyses
(IPDMAs) for various clinical topics. They found that main
and subgroup-specific effects based on observational stud-
ies and IPDMAs were similar, but despite this similarity in-
teraction effects differed. They discuss the implications of
this result. In this context, the topic addressed by Tyrrell
and his group will be increasingly more important as more
tailor-made research will require analysis within smaller
subgroups. They propose an approach to assess effective-
ness of treatments with greater power without suffering
from the time requirements of previously developed meth-
odology for this purpose. According to the authors, their
method contributes to the tools available to investigators in-
terested in studying small numbers of subjects.
Another aspect of tailoring is related to patient outcome
measurement [4]. An issue that needs more attention is
cross-cultural adaptation of health assessment scales to tar-
get groups with specific characteristics that may affect the
performance of a scale. This may necessitate adaptation
of content or criteria and may not only concern language
or international differences, but also variations between
cultural minority groups. In this context, the systematic re-
view by Uysal and co-workers, focusing on various migrant
groups, is informative. They found that for these subgroups,
cross-cultural adaptations were insufficient and that psy-
chometric properties are unknown for many translated
scales. They recommend the application of international
guidelines before studies using translated versions of health
assessment scales can be published.
The requirements that scales must meet will develop
over time, and this is an additional reason for adaptation.
This is demonstrated in a study by Lowe and his team,
who reviewed the evolution of tools for functional assess-
ment since the 1960s. They report saturation and overlap
of instruments and weaknesses in validation. These authors
also emphasize the opportunities for better integration of
new technology in developing, validating, and implement-
ing new tools while using the extensive work done in the
last 50 years, and in promoting patient acceptance, taking
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cision in measuring functional assessment in differentiating
between groups was also addressed by Khan et al. Based on
data from a cohort study of stroke patients undergoing
physiotherapy and using the upper limb Motor Assessment
Scale (UL-MAS), they showed that Rasch-based scoring
was more precise in differentiating patient groups by
post-stroke discharge destination than summative scoring.
On the interplay between general evidence and individ-
ualized care, clinical guideline development is essential. A
solid representation of the first is a basic requirement for
the latter. Brito’s group described the rigor of systematic re-
views cited in support of clinical practice guidelines in en-
docrinology. In a review of systematic reviews (SR), they
found that few recommendations in these guidelines are
supported by SRs, while the methodological quality of
SRs is suboptimal. Guideline developers may not be aware
of this and improvement is necessary.
Better guidelines may also be necessary for introducing
screening strategies into practice. Adriaensen and his co-
authors found that screening tests are often implemented
without proper evaluation. In view of this, they developed
and propose a step-wise framework of six steps, from the
assessment of technical accuracy until evaluation of impact
at patient and population levels.
Better guidance is also useful in dealing with cause-
specific competing risks, which is quite a challenge in the
analysis of longitudinal studies. Therefore, Latouche et al.
reviewed commonly used methods, identified some crucial
points, and offered practical guidance on how to synthesize
findings across causes. They illustrate their approach with
the example of hematopoietic stem cell transplantation. An-
other analytic challenge addressed in this issue is the eval-
uation of the risk of random error in meta-analyses using
trial sequential analysis (TSA). Miladinovic et al. devel-
oped a method to incorporate time-to-event outcomes into
TSA, which was demonstrated based on a review of
meta-analyses for the treatment of multiple myeloma. They
recommend that TSA should complement tools used to as-
sess systematic errors in meta-analyses, including subgroup
analyses.
For a systematic review, completeness of its evidence
base is crucial. A good method to efficiently and reliably
check this is essential for independent assessors who are
regularly provided with dossiers prepared by pharmaceuti-
cal companies to assess the added benefit of new drugs. In
this context, Waffenschmidt and co-workers evaluated the
performance of PubMed’s Related Citations (RelCit) and
a simple-structured Boolean search (SSBS) technique.
They conclude that combining the first 20 RelCits and an
SSBS in PubMed is a suitable method for this purpose.
A classic epidemiologic task is making appropriate com-
parisons between case and control groups [5]. In thiscontext, population-based sampling frames (such as the Na-
tional Health Services [NHS] register in the UK) are often
advocated. Given the challenges related to using such
a sampling frame, Macfarlane and co-authors evaluated
its use in a case-control study of vasculitis against an easily
accessible commercially available database claiming large
population coverage. It was shown that there were impor-
tant differences in self-reported measures of health and
quality of life using controls from both sources. As the au-
thors point out, this once more emphasizes the importance
of thorough prior methodological assessment in choosing
sampling frames for case-control studies.
Both for health care cost reduction and patient well-
being, appropriately decreasing hospital readmission rates
would be welcome. However, as van Walraven and Forster
point out, not all readmission rates are avoidable. There-
fore, they developed a model to determine how effective in-
terventions must be to attain specific readmission rate
reductions. Their results may have important implications
for health care planners and researchers.
When original work is assessed in review articles, au-
thors of such work may not always agree with the re-
viewers. In such cases, open feedback and discussion are
important and helpful. As to the important topic of provid-
ing evidence-based information for clinicians and making
a fair assessment of knowledge sources, Ebell and Haynes
et al exchange views on findings previously published in
this journal, and Tangri et al. and Collins discuss results re-
ported in a critical systematic review of prediction models
for chronic kidney disease.
Finally, as good writing considerably helps to convey
your message to your audience, we recommend the new
one-pager by Cals and Kotz in their monthly series on ef-
fective writing and publishing scientific papers, now ad-







[1] Knottnerus JA, Tugwell P. The patients’ perspective is key, also in
research. J Clin Epidemiol 2012;65:581e3.
[2] Srinivasan M. From the editors’ desk: Hippocrates and patient-
centered medicine. J Gen Intern Med 2012;27:135.
[3] Institute of Medicine (US) Committee on the NIH Research Priority-
Setting Process. Scientific Opportunities and Public Needs: Improv-
ing Priority Setting and Public Input at the National Institutes of
Health. Washington, DC: National Academies Press (US); 1998.
[4] Tugwell P, Knottnerus JA, Idzerda L. Tailoring patient reported out-
come measurement. J Clin Epidemiol 2010;63:1165e6.
[5] Miettinen OS. The ‘‘case-control’’ study: valid selection of subjects.
J Chronic Dis 1985;38:543e8.
